Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How do you approach second line therapy after platinum+etoposide for patients with high grade neuroendocrine colorectal carcinomas and a BRAF p.V600E mutation?
Related Questions
In G1 metastatic GEP-NET with small lesions visible on PET dotatate, very low burden of disease on CT and no clinical symptoms, are there any data to suggest early lanreotide changes natural history of disease and prolongs OS vs observation until symptoms?
What would be your next step in management for a patient with oligometastatic colon NEC who only achieved stable disease after 4 cycles of carboplatin/etoposide?
How would you approach a gastric GIST with R1 resection?
For a pedunculated rectal polyp found to be adenocarcinoma after endoscopic removal, with PNI as the only adverse feature, would you recommend additional treatment such as surgery or chemoradiation?
How do you approach a low grade intra-cholecystic papillary neoplasm of the gallbladder without invasive component and reported surgical pathology with negative margins ?
Would you treat a patient with a pancreatic head mass based on common bile duct brushings suggestive of malignancy, with repeated negative EUS biopsy?
How, if at all, are you employing ctDNA in the management of patients with colon cancer?
How would you approach a patient with Stage III gastric cancer and poor performance status who had large residual disease (ypT4N1) after neoadjuvant capecitabine and was later found to be MSI-H?
What are your top takeaways from ESMO 2023?
How do you choose between Atezolizumab/Bevacizumab (IMbrave 150) versus Durvalumab/Tremelimumab (HIMALAYA) in first-line metastatic hepatocellular cancer?